UCB (OTCMKTS:UCBJY) Sees Large Volume Increase - Here's Why

Key Points

• UCB SA experienced a significant increase in trading volume, with approximately 94,998 shares traded on Monday, marking a 118% increase from the previous session.
• The Goldman Sachs Group has upgraded UCB’s stock rating to "strong-buy", contributing to an overall average rating of "Strong Buy" from analysts.
• UCB's stock price rose by 1.2%, closing at $117.24, following its trading activity and positive analyst sentiment.

UCB SA (OTCMKTS:UCBJY - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 94,998 shares traded hands during trading, an increase of 118% from the previous session's volume of 43,591 shares.The stock last traded at $117.24 and had previously closed at $115.94.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of UCB to a "strong-buy" rating in a research report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat, UCB currently has an average rating of "Strong Buy".

UCB Stock Up 1.2%

The firm's 50-day moving average price is $102.87 and its 200-day moving average price is $95.01. The company has a quick ratio of 0.99, a current ratio of 1.36 and a debt-to-equity ratio of 0.30.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.